RT Journal Article
SR Electronic
T1 Case fatality risk of novel coronavirus diseases 2019 in China
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.03.04.20031005
DO 10.1101/2020.03.04.20031005
A1 Deng, Xiaowei
A1 Yang, Juan
A1 Wang, Wei
A1 Wang, Xiling
A1 Zhou, Jiaxin
A1 Chen, Zhiyuan
A1 Li, Jing
A1 Chen, Yinzi
A1 Yan, Han
A1 Zhang, Juanjuan
A1 Zhang, Yongli
A1 Wang, Yan
A1 Qiu, Qi
A1 Gong, Hui
A1 Wei, Xianglin
A1 Wang, Lili
A1 Sun, Kaiyuan
A1 Wu, Peng
A1 Ajelli, Marco
A1 Cowling, Benjamin J.
A1 Viboud, Cecile
A1 Yu, Hongjie
YR 2020
UL http://medrxiv.org/content/early/2020/03/06/2020.03.04.20031005.abstract
AB Objective The outbreak of novel coronavirus disease 2019 (COVID-19) imposed a substantial health burden in mainland China and remains a global epidemic threat. Our objectives are to assess the case fatality risk (CFR) among COVID-19 patients detected in mainland China, stratified by clinical category and age group.Methods We collected individual information on laboratory-confirmed COVID-19 cases from publicly available official sources from December 29, 2019 to February 23, 2020. We explored the risk factors associated with mortality. We used methods accounting for right-censoring and survival analyses to estimate the CFR among detected cases.Results Of 12,863 cases reported outside Hubei, we obtained individual records for 9,651 cases, including 62 deaths and 1,449 discharged cases. The deceased were significantly older than discharged cases (median age: 77 vs 39 years, p<0.001). 58% (36/62) were male. Older age (OR 1.18 per year; 95%CI: 1.14 to 1.22), being male (OR 2.02; 95%CI: 1.02 to 4.03), and being treated in less developed economic regions (e.g., West and Northeast vs. East, OR 3.93; 95%CI: 1.74 to 8.85) were mortality risk factors. The estimated CFR was 0.89-1.24% among all cases. The fatality risk among critical patients was 2-fold higher than that among severe and critical patients, and 24-fold higher than that among moderate, severe and critical patients.Conclusions Our estimates of CFR based on laboratory-confirmed cases ascertained outside of Hubei suggest that COVID-19 is not as severe as severe acute respiratory syndrome and Middle East respiratory syndrome, but more similar to the mortality risk of 2009 H1N1 influenza pandemic in hospitalized patients. The fatality risk of COVID-19 is higher in males and increases with age. Our study improves the severity assessment of the ongoing epidemic and can inform the COVID-19 outbreak response in China and beyond.Competing Interest StatementH.Y. has received research funding from Sanofi Pasteur, GlaxoSmithKline, Yichang HEC Changjiang Pharmaceutical Company, and Shanghai Roche Pharmaceutical Company. BJC has received honoraria from Roche and Sanofi. None of those research funding is related to COVID-19. All other authors report no competing interests.Funding StatementH.Y. acknowledges financial support from the National Science Fund for Distinguished Young Scholars (No. 81525023), Key Emergency Project of Shanghai Science and Technology Committee (No. 20411950100), National Science and Technology Major Project of China (No. 2018ZX10201001-010, No. 2018ZX10713001-007, No. 2017ZX10103009-005).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesno additional data available.